Interferon-free hepatitis C treatment increases a surrogate of atherosclerotic cardiovascular disease risk in Black veterans living with HIV

Poonam Mathur; Habib O Ramadhani; Roman Kaplan; Kristen A Stafford; Amanda Theppote; Eleanor Wilson

doi:10.1097/QAD.0000000000003900

Interferon-free hepatitis C treatment increases a surrogate of atherosclerotic cardiovascular disease risk in Black veterans living with HIV

AIDS. 2024 Jul 15;38(9):1437-1439. doi: 10.1097/QAD.0000000000003900. Epub 2024 Jun 27.

Authors

Poonam Mathur¹, Habib O Ramadhani¹, Roman Kaplan², Kristen A Stafford¹, Amanda Theppote³, Eleanor Wilson^{1

2}

Affiliations

¹ Institute of Human Virology, University of Maryland School of Medicine.
² Baltimore VA Medical Healthcare Center, Baltimore, MD.
³ Oschner Medical Center, New Orleans, LA, USA.

PMID: 38932748
DOI: 10.1097/QAD.0000000000003900

Abstract

Veterans living with HIV (VLWH) and hepatitis C virus (HCV) co-infection have an exacerbated risk of cardiovascular disease (CVD). It is unknown if HCV cure reduces CVD risk in this population. We evaluated changes in low-density lipoprotein (LDL), as a surrogate of CVD risk, 18 months after HCV cure in VLWH. We found significant increases in LDL in VLWH with advanced fibrosis, potentially increasing CVD risk. Lower LDL thresholds to initiate lipid-lowering therapies in VLWH after HCV cure may be warranted.

MeSH terms

Adult
Antiviral Agents / therapeutic use
Atherosclerosis
Cardiovascular Diseases
Coinfection
Female
HIV Infections* / complications
HIV Infections* / drug therapy
Hepatitis C / complications
Hepatitis C / drug therapy
Hepatitis C, Chronic* / complications
Hepatitis C, Chronic* / drug therapy
Humans
Lipoproteins, LDL / blood
Male
Middle Aged
Risk Assessment
Veterans*

Substances

Lipoproteins, LDL
Antiviral Agents